Amneal Pharmaceuticals Inc. has named a new chief scientific officer, it announced Tuesday, as its current CSO departs later this spring.
The Bridgewater-based pharmaceutical company said in a news release that Pradeep Bhadauria has joined the firm from Apotex Inc., where he was executive vice president, global research and development.
“We are excited to have Pradeep join our leadership team at this important moment for Amneal,” CEO and President Rob Stewart said in a prepared statement. “His deep R&D expertise across nearly all dosage forms and demonstrated strength in developing complex generics and other difficult-to-formulate products will be a strong asset to our company as we continue to diversify our pipeline and portfolio.”
Effective immediately, Bhadauria will succeed Shankar Hariharan, who is leaving Amneal on May 24.
“I would like to thank Shankar for his exceptional contributions during the last nine years with Amneal,” Stewart said. “His leadership and vision have helped deliver the company to the strong position it stands in today.”
Before Apotex, Bhadauria, who has more than 20 years’ experience leading development capabilities for pharma firms, was a vice president with Allergan/Actavis.
“I am thrilled to be joining Amneal at this exciting time for the company,” he said in a statement. “I look forward to working closely with Amneal’s excellent scientific affairs team to help advance and expand the company’s compelling pipeline and continue bringing important treatment options to patients.”
